Short and Intermediate Term Effect of Dapagliflozin on Left Ventricular Remodeling in Anterior STEMI Patients
STEMI
About this trial
This is an interventional treatment trial for STEMI
Eligibility Criteria
Inclusion Criteria: STEMI with time from symptom onset of <48 hours duration. Capable of giving signed informed consent. Exclusion Criteria: Patients with a history of old myocardial infarction. Patients with a history of previous coronary artery bypass surgery (CABG). Hemodynamically unstable patients. Patients with suboptimal echocardiographic images Patients with any cardiac rhythm other than sinus rhythm. Unsuccessful angiographic reperfusion (Thrombolysis In Myocardial Infarction [TIMI] flow grade <2). Patients with renal dysfunction. (GFR<30mmol/L). Patients who have recently undergone immunosuppressive therapy. Patients with a history of recurrent urinary tract infections. Patients who are known to be allergic to SGLT-2 inhibitors. Chronic symptomatic heart failure within the last year and known reduced ejection fraction (LVEF≤40 %), documented before the current MI hospitalization. Severe hepatic impairment (Child-Pugh class C) at the time of inclusion into the trial. Any other non cardiovascular diseases, such as active malignancy requiring treatment at the time of screening or with a life expectancy of fewer than two years based on the investigator´s clinical judgment. Currently on treatment with a sodium-glucose co-transporter 2 inhibitor (SGLT2-inhibitors).
Sites / Locations
- Helwan UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
No Intervention
Active Comparator
No Intervention
Dapagliflozin use in diabetic patients with anterior STEMI
diabetic patients with anterior STEMI without Dapagliflozin
Dapagliflozin use in non-diabetic patients with anterior STEMI
Non-diabetic patients with anterior STEMI without Dapagliflozin